Article Text

other Versions

PDF
Paper
How to keep high-risk studies ethical: classifying candidate solutions
  1. Nir Eyal
  1. Correspondence to Professor Nir Eyal, Department of Global Health and Population, Harvard TH Chan School of Public Health, Harvard University, 02115 Boston, MA, USA; neyal{at}hsph.harvard.edu

Abstract

This article lays out a wide spectrum of candidate ethical solutions for the challenge on which this JME symposium focuses: the benefit:risk ratio challenge to some early-phase HIV cure and remission studies. These candidate solutions fall into four categories: ones that seek to reduce risks in early-phase HIV cure and remission studies, ones that enhance the benefits for these studies’ participants (or show that those were adequate in the first place), ones that focus on participants’ free and informed consent to participate and ones according to whom the large benefits to non-participants can defeat considerations about individual participant net risks. In so doing, this article also structures the rest of the symposium.

  • HIV Infection and AIDS
  • Research Ethics
  • Ethics

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles